Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment

[1] Pardanani A(2011)Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis J Clin Oncol 29 789-796

[2] Gotlib JR(2015)A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis Blood Cancer J 5 e335-421

[3] Jamieson C(2014)A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers J Clin Pharmacol 54 415-321

[4] Cortes JE(2015)Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): results from two phase I studies in healthy volunteers Clin Pharmacol Drug Dev 4 315-282

[5] Talpaz M(1984)Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease Eur J Drug Metab Pharmacokinet 9 275-192

[6] Stone RM(1998)Effect of hepatic insufficiency on pharmacokinetics and drug dosing Pharm World Sci 20 183-1161

[7] Silverman MH(2008)Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction Eur J Clin Pharmacol 64 1147-773

[8] Gilliland DG(2009)Pharmacokinetics and dosage adjustment in patients with renal dysfunction Eur J Clin Pharmacol 65 757-3133

[9] Shorr J(2009)Portal hypertension secondary to myelofibrosis with myeloid metaplasia: a study of 13 cases World J Gastroenterol 15 3128-2901

[10] Tefferi A(2009)New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Blood 113 2895-1708

[1] Pardanani A(2011)Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis J Clin Oncol 29 789-796

[2] Gotlib JR(2015)A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis Blood Cancer J 5 e335-421

[3] Jamieson C(2014)A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers J Clin Pharmacol 54 415-321

[4] Cortes JE(2015)Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): results from two phase I studies in healthy volunteers Clin Pharmacol Drug Dev 4 315-282

[5] Talpaz M(1984)Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease Eur J Drug Metab Pharmacokinet 9 275-192

[6] Stone RM(1998)Effect of hepatic insufficiency on pharmacokinetics and drug dosing Pharm World Sci 20 183-1161

[7] Silverman MH(2008)Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction Eur J Clin Pharmacol 64 1147-773

[8] Gilliland DG(2009)Pharmacokinetics and dosage adjustment in patients with renal dysfunction Eur J Clin Pharmacol 65 757-3133

[9] Shorr J(2009)Portal hypertension secondary to myelofibrosis with myeloid metaplasia: a study of 13 cases World J Gastroenterol 15 3128-2901

[10] Tefferi A(2009)New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Blood 113 2895-1708